Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2
Journal of Clinical Oncology · 20.03.2023 · 41 (9) · 1703-1713
DOI: 10.1200/jco.22.01239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.03.2023. Verfasst von Siddhartha Yadav und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Breast Neoplasms, Genetic Predisposition to Disease. Die Arbeit wurde bisher 169-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
PURPOSE To estimate the risk of contralateral breast cancer (CBC) among women with germline pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2. METHODS The study population included 15,104 prospectively followed women within the CARRIERS study treated with ipsilateral surgery for invasive breast cancer. The risk of CBC was estimated for PV carriers in each gene compared with women without PVs in a multivariate proportional hazard regression analysis accounting for the competing risk of death and adjusting for patient and tumor characteristics. The primary analyses focused on the overall cohort and on women from the general population. Secondary analyses examined associations by race/ethnicity, age at primary breast cancer diagnosis, menopausal status, and tumor estrogen receptor (ER) status. RESULTS Germline BRCA1, BRCA2, and CHEK2 PV carriers with breast cancer were at significantly elevated risk (hazard ratio > 1.9) of CBC, whereas only the PALB2 PV carriers with ER-negative breast cancer had elevated risks (hazard ratio, 2.9). By contrast, ATM PV carriers did not have significantly increased CBC risks. African American PV carriers had similarly elevated risks of CBC as non-Hispanic White PV carriers. Among premenopausal women, the 10-year cumulative incidence of CBC was estimated to be 33% for BRCA1, 27% for BRCA2, and 13% for CHEK2 PV carriers with breast cancer and 35% for PALB2 PV carriers with ER-negative breast cancer. The 10-year cumulative incidence of CBC among postmenopausal PV carriers was 12% for BRCA1, 9% for BRCA2, and 4% for CHEK2. CONCLUSION Women diagnosed with breast cancer and known to carry germline PVs in BRCA1, BRCA2, CHEK2, or PALB2 are at substantially increased risk of CBC and may benefit from enhanced surveillance and risk reduction strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Mayo Clinic, Rochester, MN.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
- Department of Public Health Sciences, University of Chicago, Chicago, IL.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN.
- Department of Population Science, American Cancer Society, Atlanta, GA.
ORCID-Profile: Siddhartha Yadav, Nicholas J Boddicker, Jie Na, Eric C Polley, Chunling Hu, Steven N Hart, Nicole Larson, Lauren R Teras, Susan L Neuhausen, Elena Martinez, Christopher Haiman, Fei Chen, Kathryn J Ruddy, Esther M John, Allison W Kurian, Dale P Sandler, Katie M O'Brien, Jack A Taylor, Hoda Anton-Culver, Argyrios Ziogas, Gary Zirpoli, David E Goldgar, Julie R Palmer, Susan M Domchek, Jeffrey N Weitzel, Katherine L Nathanson, Peter Kraft, Fergus J Couch
Förderung
- NCI NIH HHS
- Intramural NIH HHS
Zitieren
APA
Yadav, S., Boddicker, N. J., Na, J., Polley, E. C., Hu, C., Hart, S. N., Gnanaolivu, R. D., Larson, N., Holtegaard, S., Huang, H., Dunn, C. A., Teras, L. R., Patel, A. V., Lacey, J. V., Neuhausen, S. L., Martinez, E., Haiman, C., Chen, F., Ruddy, K. J., …, & Couch, F. J. (2023). Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2. Journal of Clinical Oncology, 41(9), 1703-1713. https://doi.org/10.1200/jco.22.01239
Vancouver
Yadav S, Boddicker NJ, Na J, Polley EC, Hu C, Hart SN, et al. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2. Journal of Clinical Oncology. 2023;41(9):1703-1713. doi:10.1200/jco.22.01239
BibTeX
@article{Yadav2023,
author = {Yadav, Siddhartha and Boddicker, Nicholas J and Na, Jie and Polley, Eric C and Hu, Chunling and Hart, Steven N and Gnanaolivu, Rohan D and Larson, Nicole and Holtegaard, Susan and Huang, Huaizhi and Dunn, Carolyn A and Teras, Lauren R and Patel, Alpa V and Lacey, James V and Neuhausen, Susan L and Martinez, Elena and Haiman, Christopher and Chen, Fei and Ruddy, Kathryn J and Olson, Janet E and John, Esther M and Kurian, Allison W and Sandler, Dale P and O'Brien, Katie M and Taylor, Jack A and Weinberg, Clarice R and Anton-Culver, Hoda and Ziogas, Argyrios and Zirpoli, Gary and Goldgar, David E and Palmer, Julie R and Domchek, Susan M and Weitzel, Jeffrey N and Nathanson, Katherine L and Kraft, Peter and Couch, Fergus J},
title = {Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {9},
pages = {1703--1713},
doi = {10.1200/jco.22.01239}
}
EUVIMED